Evidence map›Paper›PMID 42512329›Full record

ArticleCancers2026

Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer.

Van Khanh Nguyen, Hisashi Kosaka, Kosuke Matsui, Hideyuki Matsushima, Hidekazu Yamamoto, Gozo Kiguchi, Takuya Ohigashi, Thanh Tung Lai, Hoang Hai Duong, Kyoko Inoue and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Van Khanh NguyenDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Hisashi KosakaDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.ORCID 0000-0002-2926-9973
Kosuke MatsuiDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.ORCID 0000-0002-7274-0177
Hideyuki MatsushimaDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Hidekazu YamamotoDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Gozo KiguchiDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Takuya OhigashiDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Thanh Tung LaiDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.ORCID 0000-0002-4230-9781
Hoang Hai DuongDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Kyoko InoueDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Moriyasu TakadaDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Hiroki KatoDepartment of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto City 602-8566, Kyoto, Japan.
Kengo YoshiiDepartment of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto City 602-8566, Kyoto, Japan.
Takashi ItoDivision of Gastroenterology and Hepatology, the Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.ORCID 0000-0002-4148-4086
Tsukasa IkeuraDivision of Gastroenterology and Hepatology, the Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.
Makoto NaganumaDivision of Gastroenterology and Hepatology, the Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.ORCID 0000-0002-4244-3243
Masaki KaiboriDepartment of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan.ORCID 0000-0002-0577-3921

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study evaluated the association between cumulative chemotherapy exposure and overall survival (OS) in patients with advanced biliary tract cancer (BTC) and explored baseline factors associated with prolonged treatment continuation.

methodsPatients with advanced BTC receiving systemic chemotherapy were stratified by cumulative chemotherapy exposure (<8 vs. ≥8 cycles) and analyzed retrospectively. Logistic regression analysis identified baseline factors associated with receiving ≥8 chemotherapy cycles. OS was evaluated using Kaplan-Meier and landmark-adjusted time-dependent Cox proportional hazards analyses.

resultsAmong 86 patients analyzed, those receiving ≥8 chemotherapy cycles demonstrated more favorable inflammatory and nutritional profiles and lower metastatic burden. Median OS was longer in patients who received ≥8 chemotherapy cycles (n = 40) than in those who received <8 cycles (n = 46) (19.3 vs. 6.5 months, respectively; log-rank

conclusionGreater cumulative chemotherapy exposure was associated with prolonged OS in advanced BTC, with attenuation of the survival benefit beyond approximately 8 cycles. Sustained treatment exposure may partly reflect preserved physiological reserve and ability to maintain systemic therapy in real-world clinical practice.

Indexed as

biliary tract cancercumulative chemotherapy exposurelandmark analysisoverall survival

Identifiers

PMID42512329
PMCPMC13406718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.